Payment overview · 2025
General Payments
$451.19
32 reported records · 8 companies
Healthcare provider profile · identity verified
Steve Simpson, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · LITTLE ROCK, AR · NPI 1730172958
Verified facts
What the public records show
CMS Open Payments records show Steve Simpson, M.D. received $451.19 in general payments during 2025 across 32 reported records.
ABBVIE INC. accounted for 63.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 13 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 65 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 72 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $286.26 | 63.5% | 22 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $34.94 | 7.7% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $31.38 | 7.0% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $29.16 | 6.5% | 2 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $21.36 | 4.7% | 1 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $17.38 | 3.9% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $17.17 | 3.8% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $13.54 | 3.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $451.19 | 32 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $166.60 | 10 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $163.44 | 9 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $104.48 | 11 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $34.94 | 2 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $34.94 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $29.16 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $29.16 | 2 | 2025 |
Source payment records
|
|||||
| SPRAVATO Normalized: spravato |
Drug | Janssen Pharmaceuticals, Inc | $21.36 | 1 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $17.38 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $17.17 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $17.17 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $14.20 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $13.54 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
65 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
72 | 15 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 593 | 138 |
| Amlodipine Besylate | Amlodipine Besylate | 578 | 126 |
| Omeprazole | Omeprazole | 394 | 97 |
| Levothyroxine Sodium | Levothyroxine Sodium | 351 | 76 |
| Metoprolol Succinate | Metoprolol Succinate | 339 | 67 |
| Hydrochlorothiazide | Hydrochlorothiazide | 286 | 72 |
| Alprazolam | Alprazolam | 285 | 51 |
| Losartan Potassium | Losartan Potassium | 264 | 63 |
| Lisinopril | Lisinopril | 258 | 57 |
| Glimepiride | Glimepiride | 210 | 45 |
| Potassium Chloride | Potassium Chloride | 206 | 56 |
| Clonazepam | Clonazepam | 201 | 34 |
| Zolpidem Tartrate | Zolpidem Tartrate | 200 | 34 |
| Metformin Hcl Er | Metformin Hcl | 197 | 50 |
| Pantoprazole Sodium | Pantoprazole Sodium | 187 | 41 |
| Trazodone Hcl | Trazodone Hcl | 183 | 36 |
| Metformin Hcl | Metformin Hcl | 181 | 42 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 175 | 48 |
| Gabapentin | Gabapentin | 173 | 42 |
| Tamsulosin Hcl | Tamsulosin Hcl | 173 | 36 |
| Simvastatin | Simvastatin | 171 | 37 |
| Diclofenac Sodium | Diclofenac Sodium | 158 | 44 |
| Prednisone | Prednisone | 158 | 110 |
| Furosemide | Furosemide | 137 | 40 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 136 | 28 |
| Temazepam | Temazepam | 128 | 29 |
| Meloxicam | Meloxicam | 125 | 47 |
| Tramadol Hcl | Tramadol Hcl | 122 | 33 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 118 | 45 |
| Duloxetine Hcl | Duloxetine Hcl | 113 | 23 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 108 | 19 |
| Pioglitazone Hcl | Pioglitazone Hcl | 107 | 21 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 105 | 22 |
| Metoprolol Tartrate | Metoprolol Tartrate | 104 | 23 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 102 | 21 |
| Escitalopram Oxalate | Escitalopram Oxalate | 94 | 19 |
| Pravastatin Sodium | Pravastatin Sodium | 93 | 25 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 92 | 32 |
| Azithromycin | Azithromycin | 90 | 71 |
| Allopurinol | Allopurinol | 86 | 21 |
| Amoxicillin | Amoxicillin | 86 | 67 |
| Fluoxetine Hcl | Fluoxetine Hcl | 82 | 19 |
| Sertraline Hcl | Sertraline Hcl | 79 | 20 |
| Clopidogrel | Clopidogrel Bisulfate | 75 | 16 |
| Ozempic | Semaglutide | 72 | 15 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 71 | 15 |
| Bupropion Xl | Bupropion Hcl | 70 | 22 |
| Ropinirole Hcl | Ropinirole Hcl | 70 | 16 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 66 | 13 |
| Synthroid | Levothyroxine Sodium | 65 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 63 | 28 |
| Eszopiclone | Eszopiclone | 62 | 13 |
| Pregabalin | Pregabalin | 62 | 14 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 61 | 55 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 61 | 17 |
| Lorazepam | Lorazepam | 60 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 58 | suppressed |
| Carvedilol | Carvedilol | 57 | 14 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 55 | 11 |
| Citalopram Hbr | Citalopram Hydrobromide | 51 | 11 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 51 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 51 | 13 |
| Diazepam | Diazepam | 49 | suppressed |
| Mounjaro | Tirzepatide | 48 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 48 | 12 |
| Alendronate Sodium | Alendronate Sodium | 44 | suppressed |
| Cephalexin | Cephalexin | 41 | 31 |
| Chlorthalidone | Chlorthalidone | 40 | 13 |
| Jardiance | Empagliflozin | 40 | suppressed |
| Estradiol | Estradiol | 39 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 39 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 37 | suppressed |
| Famotidine | Famotidine | 36 | 11 |
| Paroxetine Hcl | Paroxetine Hcl | 36 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 35 | suppressed |
| Ibuprofen | Ibuprofen | 35 | 13 |
| Januvia | Sitagliptin Phosphate | 35 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 35 | 11 |
| Warfarin Sodium | Warfarin Sodium | 35 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 34 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 34 | 21 |
| Buspirone Hcl | Buspirone Hcl | 33 | suppressed |
| Cefdinir | Cefdinir | 33 | 29 |
| Celecoxib | Celecoxib | 33 | suppressed |
| Atenolol | Atenolol | 32 | suppressed |
| Baclofen | Baclofen | 32 | 19 |
| Sumatriptan Succinate | Sumatriptan Succinate | 32 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 31 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 31 | suppressed |
| Colchicine | Colchicine | 31 | suppressed |
| Eliquis | Apixaban | 31 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 30 | 22 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 28 | suppressed |
| Glipizide Er | Glipizide | 28 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 27 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 27 | 18 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 27 | suppressed |
| Valsartan | Valsartan | 27 | suppressed |
| Fenofibrate | Fenofibrate | 26 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 26 | 13 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 24 | 19 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 24 | suppressed |
| Ezetimibe | Ezetimibe | 23 | suppressed |
| Spironolactone | Spironolactone | 23 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 23 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 22 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 21 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 21 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 21 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 21 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 20 | suppressed |
| Ramipril | Ramipril | 20 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 19 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 19 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 19 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 19 | suppressed |
| Verapamil Sr | Verapamil Hcl | 19 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 18 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 17 | suppressed |
| Nifedipine Er | Nifedipine | 17 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 17 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 17 | suppressed |
| Tradjenta | Linagliptin | 17 | suppressed |
| Verapamil Er | Verapamil Hcl | 17 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 16 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 16 | suppressed |
| Levetiracetam | Levetiracetam | 16 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 16 | 15 |
| Bumetanide | Bumetanide | 15 | suppressed |
| Calcitriol | Calcitriol | 15 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 15 | suppressed |
| Finasteride | Finasteride | 15 | suppressed |
| Fluconazole | Fluconazole | 15 | suppressed |
| Topiramate | Topiramate | 15 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 14 | suppressed |
| Lansoprazole | Lansoprazole | 14 | suppressed |
| Myrbetriq | Mirabegron | 14 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 14 | suppressed |
| Acyclovir | Acyclovir | 13 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 13 | suppressed |
| Ketoconazole | Ketoconazole | 13 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Levofloxacin | Levofloxacin | 13 | 11 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 12 | 11 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 12 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 12 | suppressed |
| Imipramine Hcl | Imipramine Hcl | 12 | suppressed |
| Linzess | Linaclotide | 12 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 12 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 11 | suppressed |
| Mirtazapine | Mirtazapine | 11 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 11 | suppressed |
| Sucralfate | Sucralfate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $451.19 · 32 records | ABBVIE INC. | AREXVY, FARXIGA, Leqembi, NURTEC ODT, OTEZLA, QULIPTA, REPATHA, SHINGRIX, SPRAVATO, UBRELVY, VRAYLAR, Wegovy, ZAVZPRET | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error